DRICUi010-A
BS38A10004A
iPSC line
At European Collection of Authenticated Cell Cultures (ECACC)
A CLIP contains information about a cell line including any
specific third party obligations relating to, for example,
licensing obligations or the donor consent which affect the
use of the cell line.
A batch specific Certificate of Analysis will be available to
download once you receive your EBiSC iPSC line.
General#
Cell Line |
|
| hPSCreg Name | DRICUi010-A |
| Alternative name(s) |
BS38A10004A
|
| Cell line type | Human induced pluripotent stem cell (hiPSC) |
| Notes | Further anonymized information about the donor including demographic and clinical data will be made available on the Dementia Platforms UK data portal: https://portal.dementiasplatform.uk/ |
Provider |
|
| Depositor | UK Dementia Research Institute, Cardiff University (DRICU) |
| Owner | UK Dementia Research Institute, Cardiff University (DRICU) |
| Distributors |
EBiSC
European Collection of Authenticated Cell Cultures (ECACC)
|
| Derivation country | United Kingdom |
External Databases |
|
| hPSCreg | DRICUi010-A |
| BioSamples | SAMEA11549531 |
| ECACC | 66770099 |
| Cellosaurus | CVCL_C1PG |
| Wikidata | Q114311325 |
| CLO | CLO_0104334 |
General Information |
|
| * Is the cell line readily obtainable for third parties? |
Yes Cell line can only be used in:
Disease research
Research use: allowed
Clinical use: not allowed
Commercial use: not allowed
|
Donor Information#
General Donor Information |
|
| Sex | female |
| Ethnicity | Caucasian |
Phenotype and Disease related information (Donor) |
|
| Diseases | A disease was diagnosed.
|
Karyotyping (Donor) |
|
| Has the donor karyotype been analysed? |
Yes
Normal
Karyotyping method:
Molecular karyotyping by SNP array
http:// |
Other Genotyping (Donor) |
|
| Is there genome-wide genotyping or functional data available? |
Yes
|
External Databases (Donor) |
|
| BioSamples | SAMEA11549532 |
hIPSC Derivation#
General |
|
| Source cell type |
T-LymphocyteA thymocyte-derived lymphocyte of immunological importance that is long-lived (months to years) and is responsible for cell-mediated immunity. T lymphocyte cells form rosettes with sheep erythrocytes and, in the presence of transforming agents (mitogens), differentiate and divide. These cells have the characteristic T3 surface marker and may be further divided into subsets according to function, such as helper, cytotoxic, etc.
Synonyms
|
| Source cell origin |
BloodA liquid tissue; its major function is to transport oxygen throughout the body. It also supplies the tissues with nutrients, removes waste products, and contains various components of the immune system defending the body against infection. Several hormones also travel in the blood.
Synonyms
|
Reprogramming method |
|
| Vector type | Non-integrating |
| Vector | Sendai virus |
| Genes | |
| Is reprogramming vector detectable? |
No |
| Methods used |
PCR
|
| Notes on reprogramming vector detection | Virus undetectable at Passage 11 |
| Files and images showing reprogramming vector expressed or silenced | |
Vector free reprogramming |
|
Other |
|
| Derived under xeno-free conditions |
No |
| Derived under GMP? |
No |
| Available as clinical grade? |
No |
Culture Conditions#
The following are the depositor culture conditions, they do not refer to any specific batch.
| Surface coating | Matrigel/Geltrex | |||||||||||||||||||||
| Feeder cells |
No |
|||||||||||||||||||||
| Passage method |
Enzyme-free cell dissociation
EDTA
|
|||||||||||||||||||||
| O2 Concentration | 18 % | |||||||||||||||||||||
| CO2 Concentration | 5 % | |||||||||||||||||||||
| Medium |
Other medium:
Base medium: Advanced DMEM/F12 (Gibco Thermo Fisher 12634010)
Main protein source: Albumine Serum concentration: 0 % Supplements
|
|||||||||||||||||||||
| Has Rock inhibitor (Y27632) been used at passage previously with this cell line? | Yes |
|||||||||||||||||||||
| Has Rock inhibitor (Y27632) been used at cryo previously with this cell line? | Yes |
|||||||||||||||||||||
| Has Rock inhibitor (Y27632) been used at thaw previously with this cell line? | Yes |
Characterisation#
Analysis of Undifferentiated Cells
| Marker | Expressed | Immunostaining | RT-PCR | FACS | Enzymatic Assay | Expression Profiles |
| TRA 1-60 |
Yes |
|||||
| NANOG |
Yes |
Morphology pictures
IPMAR_DRICUi010A_Morphology.pdf
Morphology of DRICUi010A on day 2 post thaw
Differentiation Potency
| Marker | Expressed |
| C-X-C Chemokine Receptor Type 4 |
Yes |
| SRY-box transcription factor 17 |
Yes |
Morphology
IPMAR_DRICUi010A_Endoderm.pdf
IPMAR_DRICUi010A_Endoderm_ICC image
| Marker | Expressed |
| C-X-C Chemokine Receptor Type 4 |
Yes |
| BRACHYURY |
Yes |
Morphology
IPMAR_DRICUi010A_Mesoderm.pdf
IPMAR_DRICUi010A_Mesoderm_ICC image
| Marker | Expressed |
| Paired box 6 |
Yes |
| orthodenticle homeobox 2 |
Yes |
Morphology
IPMAR_DRICUi010A_Ectoderm.pdf
IPMAR_DRICUi010A_Ectoderm_ICC image
Microbiology / Virus Screening |
|
| HIV 1 | Negative |
| HIV 2 | Negative |
| Hepatitis B | Negative |
| Hepatitis C | Negative |
| Mycoplasma | Negative |
Genotyping#
Karyotyping (Cell Line) |
|
| Has the cell line karyotype been analysed? |
Yes
No gross abnormalities
Passage number: 13
Karyotyping method:
Molecular karyotyping by SNP array
http:// |
Other Genotyping (Cell Line) |
|